{
    "clinical_study": {
        "@rank": "48669", 
        "arm_group": {
            "arm_group_label": "Ublituximab + ibrutinib", 
            "arm_group_type": "Experimental", 
            "description": "Ublituximab:  IV infusion dose Days 1, 8 and 15 followed by maintenance infusions Ibrutinib:  Fixed oral daily dose"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and effectiveness of Ublituximab in\n      combination with Ibrutinib in patients with advanced hematologic malignancies."
        }, 
        "brief_title": "Ublituximab + Ibrutinib in Select B-cell Malignancies", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Chronic Lymphocytic Leukemia", 
            "Mantle Cell Lymphoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Leukemia, Lymphoid", 
                "Lymphoma", 
                "Lymphoma, Mantle-Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Confirmed Mantle Cell lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL)/Small\n             Lymphocytic Lymphoma (SLL), and other B-cell lymphoproliferative disorders as\n             approved by the Medical Monitor or Study Chair\n\n          -  Refractory to or relapsed after at least 1 prior treatment regimen\n\n          -  Eastern Cooperative Oncology Group (ECOG) score of 0 to 2\n\n        Exclusion Criteria:\n\n          -  Any major surgery, chemotherapy or immunotherapy within the last 21 days\n\n          -  Known hepatitis B virus, hepatitis C virus or HIV infection\n\n          -  Autologous hematologic stem cell transplant within 3 months of study entry.  Prior\n             Allogeneic hematologic stem cell transplant is excluded.\n\n          -  Richter's transformation, prolymphocytic leukemia or primary central nervous system\n             lymphoma"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02013128", 
            "org_study_id": "UTX-IB-104"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ublituximab + ibrutinib", 
                "description": "Ublituximab (IV infusion)", 
                "intervention_name": "Ublituximab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Ublituximab + ibrutinib", 
                "description": "Ibrutinib oral daily dose", 
                "intervention_name": "Ibrutinib", 
                "intervention_type": "Drug", 
                "other_name": "Ibrutinib (IMBRUVICA)"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 24, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Huntsville", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35805"
                    }, 
                    "name": "TG Therapeutics Investigational Trial Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tucson", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85710"
                    }, 
                    "name": "TG Therapeutics Investigational Trial Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santa Barbara", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "93105"
                    }, 
                    "name": "TG Therapeutics Investigational Trial Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boulder", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80303"
                    }, 
                    "name": "TG Therapeutics Investigational Trial Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Niles", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60714"
                    }, 
                    "name": "TG Therapeutics Investigational Trial Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Urbana", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "61801"
                    }, 
                    "name": "TG Therapeutics Investigational Trial Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bethesda", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "20817"
                    }, 
                    "name": "TG Therapeutics Investigational Trial Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Morristown", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07962"
                    }, 
                    "name": "TG Therapeutics Investigational Trial Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97213"
                    }, 
                    "name": "TG Therapeutics Investigational Trial Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Springfield", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97477"
                    }, 
                    "name": "TG Therapeutics Investigational Trial Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Greenville", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29615"
                    }, 
                    "name": "TG Therapeutics Investigational Trial Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Memphis", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "38120"
                    }, 
                    "name": "TG Therapeutics Investigational Trial Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Austin", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78705"
                    }, 
                    "name": "TG Therapeutics Investigational Trial Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75230"
                    }, 
                    "name": "TG Therapeutics Investigational Trial Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tyler", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75702"
                    }, 
                    "name": "TG Therapeutics Investigational Trial Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Blacksburg", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "24060"
                    }, 
                    "name": "TG Therapeutics Investigational Trial Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fairfax", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "22031"
                    }, 
                    "name": "TG Therapeutics Investigational Trial Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vancouver", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98684"
                    }, 
                    "name": "TG Therapeutics Investigational Trial Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multi-center Phase II Study With Safety Run-in Evaluating the Efficacy and Safety of Ublituximab in Combination With Ibrutinib in Patients With Select B-Cell Malignancies", 
        "overall_contact": {
            "email": "clinicalsupport@tgtxinc.com", 
            "last_name": "TG Therapeutics Clinical Support Team", 
            "phone": "212-554-4484"
        }, 
        "overall_official": [
            {
                "affiliation": "Columiba University Medical Center", 
                "last_name": "Owen A O'Connor, MD, PhD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Willamette Valley Cancer Institute", 
                "last_name": "Jeff Sharman, MD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To determine the incidence of adverse events, any potential abnormal laboratory results and any dose-limiting toxicities", 
            "measure": "To evaluate the safety of ublituximab in combination with ibrutinib in patients with select B-cell malignancies", 
            "safety_issue": "No", 
            "time_frame": "28 days (1 cycle of therapy)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02013128"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To assess the overall response rate (ORR) in patients with hematologic malignancies treated with Ublituximab in combination with Ibrutinib", 
            "measure": "Overall Response Rate", 
            "safety_issue": "No", 
            "time_frame": "Up to 1 year"
        }, 
        "source": "TG Therapeutics, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "TG Therapeutics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}